Security analyst Michael Robinson spent 14 months mining thousands of legal filings to uncover who malicious insiders really are, how they operate, and why traditional detection models keep missing them.
From Chef to CISO: An Empathy-First Approach to Cybersecurity Leadership
Myke Lyons, CISO at data-processing SaaS company Cribl, shares how he cooked up an unconventional journey from culinary school to cybersecurity leadership.
The AI Trust Paradox: Why Security Teams Fear Automated Remediation
Security teams invest in AI for automated remediation but hesitate to trust it fully due to fears of unintended consequences and lack of transparency.
YouTube Ghost Network Utilizes Spooky Tactics to Target Users
The malware operation uses compromised accounts and bot networks to distribute infostealers and has tripled its output in 2025.
Oracle EBS Attack Victims May Be More Numerous Than Expected
Numerous organizations have been attacked via Oracle EBS zero-day CVE-2025-61882, and evidence suggests more like Schneider Electric could be on that list.
Lilly keeps up legal fight against GLP-1 compounders
Despite recent setbacks in court, Eli Lilly is doubling down on its fight against compounded weight loss drugs. The pharma giant told Endpoints News on Tuesday that it plans to refile its complaint against the …
FDA clears at-home use for Delix’s next neuroplastogen study
Delix has early-stage clinical data showing that its non-hallucinogenic neuroplastogen could be a future depression treatment option. It also said the FDA cleared at-home use of its candidate in a future Phase 2 study. …
Everlywell’s at-home testing business evolution
It had been years since I last saw Julia Cheek in person. Cheek, the CEO of at-home testing company Everlywell, reminded me when I last saw her in 2019 the company was making about …
FDA’s biosimilars director says agency seeks to ‘streamline’ development
BETHESDA, MD — The FDA’s top biosimilars expert Sarah Yim said the agency is looking to take “a little less” of an “algorithmic approach” to reviewing applications, with the goal of accelerating the development of the …
Eli Lilly, Nvidia say they’ll build pharma’s most powerful supercomputer
Eli Lilly and Nvidia have agreed to build what they claim will be life sciences’ most powerful supercomputer, with plans to train ever-larger AI models to discover and design medicines. “It will allow us to …